CCL2 and COVID-19: It has been reported that acalabrutinib and ibrutinib are capable of inhibiting monocyte, macrophage, and neutrophil activation, thereby reducing the levels of inflammatory cytokines and chemokines such as IL-6, TNFα, IL-1, IFNγ and MCP-1 in patients with severe COVID-19 (15).